Monoclonal antibodies (MAbs) were elicited with inactivated, purified foot-andmouth disease virus (FMDV) type O1 strain Brugge (140S) and with 12S protein subunits. Each MAb was tested for its capacity to bind to FMDV O1 Brugge 140S virions, 12S subunits and purified VP1 by radioimmunoassay (RIA) and to neutralize viral infectivity in mouse protection assays. Those MAbs which reacted only with 12S subunits in RIA did not neutralize infectious virus. One MAb, 12FE9.2.1, reacted with 140S, 12S and purified VP 1 of FMDV O1 Brugge and neutralized infectious virus. Reactions with different biosynthetic FMDV type O1 Campos VP1 polypeptides localized the binding site of 12FE9.2.1 between amino acid residues 135 and 172. Eight MAbs reacted with both 140S virions and 12S subunits and neutralized infectious virus. Monoclonal antibodies that reacted only with 12S protein subunits or with 140S, 12S and VP1 did not compete in RIA with 140S/12S-reactive neutralizing MAbs for 12S binding sites. The ability of 140S/12S-reactive MAbs to compete for the 12S binding site defined by MAb 10GA4.2.2 was directly related to their capacity to neutralize infectious virus, suggesting that these MAbs were all affecting a single neutralization site. In mouse protection and plaque reduction neutralization assays, 10GA4.2.2 and 12FE9.2.1 were equally effective in neutralizing the homologous FMDV type O1 Brugge, and in cross-neutralization assays both exhibited high titres against four additional strains of type O1 FMDV.
INTRODUCTION
Antibody to foot-and-mouth disease virus (FMDV) plays a major role in determining the immunity of animals to the disease. The use of specific antisera in virus neutralization assays is a powerful method for identifying components of FMDV that play a significant role in eliciting an immune response. The intact FMD virion is composed of 60 copies each of four structural polypeptides, VP1 to VP4 (Bachrach, 1977) . Evidence from several lines of investigation including analysis of isolated capsid proteins following protease treatment (Strohmaier et al., 1982) and iodination of intact virus indicate that VP1 is the most exposed polypeptide on the surface of the virion. In addition, antisera to isolated VP 1 react with 140S particles while antisera to isolated VP2 and VP3 do not (Bachrach et al., 1977) . Immunization of animals with purified VP1 and fragments of VP1 demonstrated that this molecule carries determinants which elicit neutralizing antibodies (Laporte et al., 1973; Kaaden et al., 1977) and protective immunity (Bachrach et al., 1975 (Bachrach et al., , 1979 . Based on these findings subunit vaccines containing biosynthetic VP1 molecules (Kleid et al., 1981 or small organically synthesized peptides of VP 1 covalently bound to large carrier molecules (Bittle et al., 1982) have been developed.
While much work has been devoted to defining immunogenic determinants on isolated VP1, many workers have demonstrated the existence of neutralization epitopes associated with higher order structures of the virion. Breakdown of FMDV in vitro results in the liberation of the RNA and 12S protein subunits containing equimolar amounts of VP1, VP2 and VP3 (Vande Woude et al., 1972) . Isolated 12S particles are immunogenic (Morgan et al., 1980) and able to absorb completely the neutralizing capacity of an antiserum to isolated VP 1 (Hardy & Moore, 1981) . Absorption of polyclonal antisera to whole virus with 12S subunits, however, only removes a portion of the neutralizing activity (Cowan, 1968; Brown & Smale, 1970) indicating the existence of conformation-dependent neutralization epitopes on the surface of the virion. Indeed, neutralizing and non-neutralizing monoclonal antibodies (MAbs) have been isolated which react only with the 140S antigen or with both 140S and 12S particles (Meloen et aL, 1983; Baxtet aL, 1984; Morgan et al., 1984; Ouldridge et al., 1984) . Furthermore, there is evidence with both types O and A FMDV for multiple conformation-specific neutralization epitopes on the virion surface Ouldridge et al., 1984) .
The present communication reports the production and characterization of MAbs to FMDV type O1 Brugge t40S virions and 12S subunits and identification of at least two unique epitopes involved in neutralization of several strains of type O1 FMDV. One of these is conformationally determined and present both on 140S virions and 12S subunits while the other is determined by a continuous sequence of amino acids on VPI.
METHODS
Viruses. Stocks of FMDV type Or, subtypes Brugge, Campos, Caseros and Kaufbeuren were isolated from bovine tongue tissue, passaged several times in BHK-21 cell cultures and stored at -70 °C (Polatnick & Bachrach, 1977) . FMDV O1 BFS was obtained from the Animal Virus Research Institute, Pirbright, U.K., and passaged similarly.
FMDV 01 Brugge antigens. Intact virions (140S) were harvested from FMDV-infected roller bottle cultures of BHK cells by precipitation with polyethylene glycol (Wagner et al., 1970) and CsCI density gradient centrifugation (Bachrach et al., 1964) . The purified virus was dialysed against Tris-buffered saline (TBS; 0.05 M-Tris-HC1, 0.3 MNaC1, pH 7-5), inactivated with 3 mM-ethylenimine (Bahnemann, 1975) , and quantified by optical density (Bachrach et al., 1964) .
The 12S protein subunits were prepared by dialysis of the purified, inactivated 140S virions against citratephosphate buffer pH 4-5 (Cowan, 1968) , followed by dialysis in TBS and clarification by centrifugation.
Purified VPI was prepared from urea-disrupted, whole inactivated FMDV O1 Brugge by DEAE anionexchange chromatography (Bernard et al., 1974) .
Biosynthetic FMDV 01 Campos VP1 polypeptides. Chimeric Escherichia coli--FMDV polypeptides were biosynthetically produced in E. coli containing recombinant plasmids (kindly provided by Genentech, South San Francisco, Ca., U.S.A.). The nucleic acid sequences coding for the viral polypeptides and the deduced amino acid sequences have been previously reported (Yansura et al., 1983) .
Monoclonal antibodies. Adult BALB/c mice were immunized with three 100 lag doses of either purified FMDV O1 Brugge 140S or 12S particles. The first and second (49 days after primary immunization) doses of antigen were given subcutaneously in Freund's complete adjuvant. The final dose was administered intraperitoneally without adjuvant at 60 and 165 days after primary immunization for 12S and 140S respectively. MAbs were prepared by the procedures of K6hler & Milstein (1975) according to standard methods (Letchworth & Appleton, 1984) . Hybridomas were grown in minimal essential medium (MEM; Gibco) supplemented with 20% foetal bovine serum (FBS). Hybridoma culture supernatants were analysed by radioimmunoassay (RIA) for the presence of FMDV O1 Brugge 140S, 12S and VP1 reactive antibodies. Hybridomas producing antibodies of interest were cloned by limiting dilution and stored in liquid nitrogen. Isotypes of the MAbs were determined by Ouchterlony reactions with isotype-specific antisera (Litton Bionetics, Kensington, Md., U.S.A.) in 1% agar buffered with 1 Mglycine, 0-0125 M-sodium barbital, 0.15 M-NaCI, pH 7.9 (GBS). Only antibodies from monoclonal hybridoma cultures were used in these studies. The two numbers following the hybridoma designation indicate which clones were picked during cloning and for simplicity wilI be replaced by an asterisk (e.g. 12FE9* replaces 12FE9.2.1).
Radial immunodiffusion. A standardized radial immunodiffusion (RID) assay was developed for determining MAb concentration in hybridoma culture supernatants. Rabbit anti-mouse sarcoma ascites (Ra-a-MSA) antibodies were precipitated from whole serum with 40% saturated ammonium sulphate and dialysed against TBS. Immuno-plates (2.5 × 7.5 cm, Hyland, Costa Mesa, Ca., U.S.A.) were filled with 3 ml 0.05% Ra-a-MSA, 0-7% agarose and stored at 4 °C in a H20-saturated atmosphere. A MAb (10GB4*) purified by goat anti-mouse immunoglobulin (G-a-MIg) affinity chromatography and quantified by the Bio-Rad protein assay was used as a standard. Purified 10GB4* was diluted in GBS and 20 ~tl of each dilution was added to 5 mm diameter wells cut in the agarose. The plates were incubated for 5 days at room temperature and a standard graph was constructed by plotting the diameter of the precipitin rings squared against antibody concentration. Hybridoma culture supernatants were added to wells and MAb concentrations determined from the diameters of the precipitin rings and the standard graph.
Radioimmunoassay. RadiolabeUed virions were prepared by incubating 250 lag of CsCl-purified 140S in 50 p. 
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2085 TBS with 0.5 mCi 125Iodine (Amersham) and two Iodobeads (Pierce Chemical, Rockford, IU., U.S.A.) for 15 min at room temperature. The reaction mixture was transferred to a tube containing 5 p-1 TBS, 2 p-1 10~o 2-mercaptoethanol and 2 I11 0.1 M-NaI and unincorporated 12sI was separated from labelled virus by gel filtration through Sepbadex G-25 (Pharmacia) using TBS containing 0.5 mM-NaI and 0.02~ bovine serum albumin (BSA). Prior to use in RIA the labelled virus was repurified by centrifugation on a 20 to 45~ discontinuous sucrose gradient (45 000 r.p.m., 1.5 h, 4 °C). Dilutions were made in 0.12 M-boric acid, 0.02 M-sodium borate, 0.15 M-NaC1, pH 8 (RIA buffer) containing 0.1 ~ BSA (RIA/BSA). In order to determine reactivity to 140S virions, MAb hybridoma culture supernatants (50 p-l) were mixed with purified 12sI-140S (50 p-l, 10000 c.p.m.) and incubated (1 h, 37 °C). Rabbit anti-mouse immunoglobulin (50 p-l, 1 : 1000) was added and after 1 h at 37 °C antigen-antibody complexes were reacted with 1 ~ Protein A-bearing Staphylococcus aureus (15 rain, 37 °C) and pelleted by centrifugation (20000 r.p.m., 2 rain). The precipitates were washed in RIA buffer containing 0.05~ Tween 20 (RIA/Tween) and the amount of radioactivity associated with the pellets was determined in a gamma scintillation counter. Solutions of FMDV O1 Brugge 12S subunits (0.4 p.g/50 p-1 RIA buffer), VP 1 (0.7 p-g/50 p-10-2 M-ethylmorpholine, 6 M-urea, 10 mM-2-mercaptoethanol, pH 8.5) and FMDV Oz Campos biosynthetic VP 1 polypeptides (0~25 p-g/50 ~tl 6 M-urea, 0-014 M-Tris-HC1, 0.15 M-NaCI, 1 ~ 2-mercaptoethanol, pH 8.3) were adsorbed directly to the surface of Immulon no. 2 plastic wells (Dynatech) overnight at 4 °C. Wells were blocked with RIA buffer, 10~ FBS (250 p-l) overnight at 4 °C and washed three times with RIA/Tween. Following incubation (1 h, 37 °C) with MAbs (50 lal) the wells were washed, reacted with 12SI-G-a-MIg (50 p-l), washed a final time and the radioactivity associated with each well was measured in a gamma counter. The G-a-MIg (100 p-g/100 p-l; Boehringer Mannheim) was labelled by the procedure given above for labelling virus particles.
Competitive 12S binding assay. The MAb 10GB4* was purified by G-a-MIg affinity chromatography and labelled with t25I as described above. The competing MAbs (30 p-g/ml) were diluted in RIA/BSA and 50 p.1 of each dilution was incubated (1 h, 37 °C) in Immulon wells which had been coated with FMDV O1 Brugge 12S (0-4 ~tg/50 p-l) subunits and blocked with FBS. The wells were washed three times with RIA/Tween, reacted with 12sI-10GB4* (50 p.l, 1 h, 37 °C), washed and counted.
Mouse protection assay. Dilutions of MAbs in MEM were mixed with an equal volume of a FMDV suspension, incubated (1 h, room temperature) and inoculated (100 LDs0 virus per 30 p.1 dose) intraperitoneally into one litter (eight mice) of 10-day-old mice. The number of mice alive 5 days post-inoculation was used to calculate the 50 mouse protective dose (MPDs0) titre of the antibody by the Spearman-K/irber method (Finney, 1964) .
Plaque reduction neutralization assay. Dilutions of MAbs in MEM were incubated with an equal volume of a FMDV suspension (100 p.f.u./0.1 ml) for 1 h at room temperature. Monolayers of LF-BK cells (Swaney et al., 1982) were inoculated with the reaction mixtures (0.1 ml) and the virus was allowed to adsorb to the cells (1 h, 37 °C, 4~ CO2 in air) before overlaying with methylcellulose (4000 centipoise, 1~ in MEM). Plates were incubated (24 h, 37 °C, 4~ CO2 in air), fixed with formalin and stained with crystal violet. Seventy percent plaque reduction neutralization (PRNT0) titres were determined using the logit-log transformation (Finney, 1964) .
RESULTS
The majority of the MAbs isolated were of the IgG isotype and all contained kappa light chains (Table 1) . Only one MAb of the IgM isotype was isolated (12DC11") and it was specific for 12S subunits in RIA (Table 1) and precipitated 12S subunits in Ouchterlony assays (data not shown). The concentrations of MAbs in hybridoma culture supernatants determined by RID ranged from 23 to 204 p.g/ml, with a median concentration of 58 ~tg/ml. All 16 of these MAbs reacted with 12S in RIA. Seven of the MAbs were specific for the 12S antigen and thus did not neutralize viral infectivity. Two of the MAbs derived from mice immunized with purified 140S virions reacted with 12S subunits but not with either 140S virions or VPI. All of the 140S/12S-reactive MAbs described here exhibited at least some neutralizing activity in mouse protection assays.
The ability of MAbs elicited by FMDV O1 Brugge antigens to neutralize other strains of type O~ FMDVin PRNT0 assays is shown in Table 2 . The MAbs 10GA4* and 10GF5* neutralized all five strains of type O1 FMDV tested; however, the specific activity of 10GF5* was less. The MAb 10GB4* at a concentration of 204 ~tg/ml showed some neutralization of FMDV O~ Caseros but in this assay did not neutralize the homologous O~ Brugge. The capacities of 10GA4* and 12FE9* to neutralize FMDV O1 Brugge were similar; however, 12FE9* neutralized O1 Campos and O1 Caseros poorly whereas 10GA4* showed good neutralization.
In MPDs0 assays 10GA4* and 12FE9* both had high titres to five strains of type O1 FMDV (Table 3 ). Similar to results from PRN70 assays, 10GA4* exhibited higher titres to O1 Campos (Yansura et al., 1983) is contained in the polypeptide represented at the top of the illustration. All six of the sequences shown are fused to 190 amino acids derived from the tryptophan operon of E. coli via their amino termini (left).
Numbers indicate positions of amino acids delimiting VPl-specific sequences. 2.9 2"9 1.9 2'9 2-0 2'1 1.8 * Mice were inoculated with 100 LDs0 of each virus strain. t Logarithm 50~ protective dose titres using hybridoma culture supernatants. A group of eight MAbs which reacted with 140S virions and 12S subunits in RIA were ranked according to their capacity to neutralize FMDV O1 Brugge in MPD50 assays on a per weight basis (specific neutralization capacity, Table 4 ). At a concentration of 30 ~tg/ml all of these MAbs had 12S RIA binding titres of 12800 yet each had a different capacity to neutralize. The specific neutralization capacity of these MAbs was directly related to their ability to compete for the 12S binding site recognized by 12sI-10GB4*. In general, MAbs that had high MPDso titres to O1 Brugge exhibited the highest maximum percentage inhibition and inhibited 50~ binding of 125 I_10GB4* at lower concentrations than poorly neutralizing MAbs (Fig. 2, Table 4 ). Two MAbs, 10GA4* and 10GF5*, were clearly more efficient at binding to the 10GB4* binding site than 10GB4* itself. The neutralizing MAb 12FE9* did not compete significantly with 1251-10GB4* for 12S sites while binding of the 12S-specific, non-neutralizing MAb 10ADll* actually enhanced binding of 1251-10GB4" (Fig. 2) .
DISCUSSION
Monoclonal antibodies were made to FMDV O1 Brugge for the analysis of neutralization epitopes of the virus in anticipation that such information could be used to design more efficient vaccines against FMD. All of the MAbs described here contained kappa light chains and all but one were of the IgG isotype reflecting the facts that 95 ~ of all mouse immunoglobulin molecules contain kappa light chains and that extended immunization procedures typically result in an IgG response (Goding, 1983 ). An IgM MAb was isolated which precipitated 12S antigen in agar gel diffusion assays (data not shown), and was specific for FMDV type Ot Brugge 12S subunits in RIA (Table 1) . These results are in contrast to earlier findings which suggested that IgM does not react with 12S subunits of FMDV (Brown & Smale, 1970) . In these earlier studies guineapigs were infected with live virus and 7-day serum was used as a source of IgM. One could speculate that 140S-specific epitopes are immunodominant over 12S epitopes and consequently antibody to 12S was not detected in the early response.
Repeated immunization of mice with purified 140S virions resulted in the isolation of 12S-specific MAbs. Similar findings have been reported by McCuUough & Butcher (1982) who suggest that isolation of such antibodies is very likely due to degradation of the intact virus to 12S subunits in vivo. In all cases 12S-specific MAbs did not neutralize infectious virus. Clearly, antibodies that do not bind to infectious virus cannot neutralize infectivity. Haresnape & McCahon (1983) have shown that antisera to purified VP2 and VP3 bind to isolated 12S subunits and it is possible that 12S-specific MAbs are recognizing determinants on these molecules.
In PRNTo assays MAbs to FMDV O1 Brugge neutralized other strains of type O1 FMDV demonstrating similarities between strains. However, each MAb exhibited a unique pattern of neutralization of the five strains suggesting that they could be recognizing different epitopes. In PRNTo and MPDso assays MAbs 10GA4* and 12FE9* neutralized all five strains of type O1 FMDV tested but both had lower titres in PRN~o assays to FMDV O1 Campos and Caseros than in MPDso assays. In the presence of excess sensitizing antibody (140S/12S-reactive), infectious immune complexes can form which are still able to form plaques in PRNTo assays Fig. 3 . FMDV VP1 amino acid sequences deduced from nucleotide sequences ofcDNA. The numbers indicate the position of the amino acid residue in the complete VP1 molecule. Outlined residues are different from those determined for FMDV Oi Campos VPI (Yansura et al., 1983) . A space has been added to the FMDV A12 VP1 sequence at position 143 in order to maximize homology with the type O1 sequences. The A12 sequence is from Kleid et al. (1981 ) , the O~ BFS sequence from Makoffet al. (1982) and the O1 Kaufbeuren sequence from Kurz et at. (1981) . (Hardy & Moore, 1981) . In mice such complexes might be effectively cleared from the animal by additional host factors and would not figure in the calculation of MPDso titres, thus accounting for the higher titres seen in the MPD5o assays. Monoclonal antibody 12FE9* reacts with VP1 from FMDV type O1 strains Brugge and Campos and neutralizes five strains of type O1 FMDV in MPD50 assays, demonstrating the existence of this epitope on five strains of type O i FMDV. Reaction of 12FE9* with O~ Campos VPI biosynthetic polypeptides (Fig. 1) demonstrated that the location of this neutralization epitope lies somewhere in a continuous stretch of amino acids between residues 135 and 172. The VP1 amino acid sequences from FMDV type O1 strains Kaufbeuren (Kurz et al., 1981) , BFS (Makoff et aL, 1982) , and Campos (Yansura et al., 1983) show only two differences in this region at positions 137 and 144 (Fig. 3) . Given the specificity of antibody binding it is possible that 12FE9* is binding to a sequence of amino acids between residues 138 and 143 or 145 and 172 of type O1 VPI. Furthermore, 12FE9* neither neutralizes the infectivity of nor binds to VP 1 derived from type A12 FMDV (data not shown). Amino acids 162 to170 of FMDV A 12 (Kleid et al., 1981) are identical to those of the three type O1 sequences shown in Fig. 3 and thus it is unlikely that the 12FE9* epitope is located there. Therefore, the most likely location of the neutralization epitope defined by MAb 12FE9* is between amino acids 138 and 143 or 145 and 162. The location of this neutralization epitope on FMDV O1 Campos VP 1 is similar to the location of neutralization epitopes on VP1 from FMDV O1 Kaufbeuren (Bittle et al., 1982; Pfaff et al., 1982; Strohmaier et al., 1982) and FMDV type A12 , suggesting that this area may have similar functions in different strains and types of FMDV.
Monoclonal antibodies reactive with both 140S virions and 12S subunits were not equally effective at competing for the 10GB4* 12S-binding site in competition RIA when compared at equal concentrations of antibody protein. There are a number of mechanisms by which binding of the first MAb to the 12S subunits could influence the binding of the second. It is possible that the first MAb could inhibit the binding of the second by direct steric hindrance which would be the case if the two epitopes were physically adjacent or overlapping. On the other hand, the binding of one MAb could cause a conformational change at some distant site resulting in altered binding by the second MAb. Evidence for this mechanism of action can be seen in Fig. 2 where binding of 10AD11" to 12S particles actually enhanced the binding of 1251-10GB4" at all concentrations tested. A third possibility is that both MAbs bind to the same epitope but with different affinities. The ability of 10GA4* and 10GF5* to compete more efficiently for 10GB4* binding sites on 12S subunits than 10GB4* itself suggests that these MAbs bind to the same epitope but with greater affinity. While the mechanism by which these MAbs compete for 12S binding sites remains undetermined the direct relationship between neutralization and ability to compete for 12S binding sites suggests that they are affecting a single neutralization site. One can postulate that there are relatively large areas on the surface of the virion that are functionally involved in the phenomenon of neutralization and that within these areas a number of antibody epitopes may occur. That some areas exposed on the surface of the virion are not as important as others with respect to neutralization is evidenced by the fact that on a per weight basis MAbs 12FB2* and 10GA4* have identical 12S-binding titres but very different capacities to neutralize.
Evidence for multiple neutralization sites on the surface of FMDV has been presented by many workers (Cowan, 1968; Meloen et al., 1983; Morgan et al., 1984; Ouldridge et al., 1984) .
The results presented here demonstrate the existence of at least two distinct neutralization epitopes on the surface of FMDV O1 Brugge. One of these is determined by conformation on the 140S and 12S particles and is best defined by MAb 10GA4* while the other is determined by a continuous sequence of amino acids on VP1 recognized by MAb 12FE9*. Vaccines consisting of type A VPl-specific amino acid sequences have been effective in protecting cattle and swine from infection by FMDV (Kleid et al., 1981 ; McKercher et al., 1985) presumably due to the production of antibodies to the continuous neutralization epitope located on VP1. However, eliciting protective immunity in large animals with VP1 preparations from serotype O FMDV has been more difficult to achieve (DiMarchi et al., 1986) . It is possible that with some strains of FMDV, antibody production to conformational neutralization epitopes plays a major role in determining immunity to FMD. The success of present-day inactivated whole virus vaccines may well be attributable to the presentation of both continuous and conformational neutralization epitopes. Development of technologies for synthesizing conformational epitopes would have great potential for improving synthetic vaccines.
